D-VRd Extends PFS in Newly Diagnosed Multiple Myeloma Subgroups
Belantamab Mafodotin Plus VRd Demonstrates Efficacy in Newly Diagnosed, Transplant-Eligible Myeloma
Experts Share Intriguing Early-Phase Sarcoma Studies From the 2024 ESMO Congress
Adjuvant Pembrolizumab Prolongs DFS Regardless of PD-L1 or Nodal Status in High-Risk MIBC